GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (FRA:Q8T) » Definitions » 3-Year EPS without NRI Growth Rate

OrbusNeich Medical Group Holdings (FRA:Q8T) 3-Year EPS without NRI Growth Rate : 91.60% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is OrbusNeich Medical Group Holdings 3-Year EPS without NRI Growth Rate?

OrbusNeich Medical Group Holdings's EPS without NRI for the six months ended in Jun. 2024 was €0.02.

During the past 12 months, OrbusNeich Medical Group Holdings's average EPS without NRI Growth Rate was 11.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 91.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of OrbusNeich Medical Group Holdings was 91.60% per year. The lowest was 40.40% per year. And the median was 66.00% per year.


Competitive Comparison of OrbusNeich Medical Group Holdings's 3-Year EPS without NRI Growth Rate

For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OrbusNeich Medical Group Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where OrbusNeich Medical Group Holdings's 3-Year EPS without NRI Growth Rate falls into.



OrbusNeich Medical Group Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


OrbusNeich Medical Group Holdings  (FRA:Q8T) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


OrbusNeich Medical Group Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


OrbusNeich Medical Group Holdings Business Description

Traded in Other Exchanges
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich is a China-based global medical device maker of endovascular interventional instruments with global reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's largest revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its largest product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.

OrbusNeich Medical Group Holdings Headlines

No Headlines